CeriBell, Inc. (CBLL) vs Monte Rosa Therapeutics, Inc. (GLUE)
A side-by-side comparison of CeriBell, Inc. and Monte Rosa Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBLL
CeriBell, Inc.
$24.60HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
GLUE
Monte Rosa Therapeutics, Inc.
$10.05HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — CBLL vs GLUE
growth of $100 · dividends reinvested · last 2yCBLL -0.6% (-0.3%/yr)GLUE +108.3% (+44.3%/yr)GLUE compounded faster over this window
CBLL GLUE
CBLL vs GLUE: by the numbers
- •CBLL is the larger company ($933M vs $849M market cap).
- •Both run net losses; CBLL's is the smaller (-64.73% vs -560.85% net margin).
Metrics side by side
Valuation
| Metric | CBLL | GLUE |
|---|---|---|
| P/S ratio | 9.15 | 29.55 |
| P/B ratio | 7.27 | 1.74 |
Profitability
| Metric | CBLL | GLUE |
|---|---|---|
| Gross margin | 88.90% | 92.94% |
| Operating margin | -68.62% | -43.83% |
| Net margin | -64.73% | -560.85% |
| ROE | -51.43% | -33.06% |
| ROIC | -46.54% | -28.69% |
Growth (annualized)
| Metric | CBLL | GLUE |
|---|---|---|
| Total return CAGR (5Y) | N/A | -12.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.